Invention Grant
- Patent Title: Heterocyclic compound
-
Application No.: US17042394Application Date: 2019-03-28
-
Publication No.: US11584737B2Publication Date: 2023-02-21
- Inventor: Koji Ono , Masahiro Ito , Toshio Tanaka , Moriteru Asano , Takaharu Hirayama , Jun Fujimoto , Nobuki Sakauchi , Yasuhiro Hirata , Akinori Toita , Nao Morishita , Hironori Kokubo , Yasuhiro Imaeda , Hironobu Maezaki , Douglas Robert Cary , Ryo Mizojiri , Nobuo Cho , Hiroshi Banno , Hidekazu Tokuhara , Yasuyoshi Arikawa
- Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
- Applicant Address: JP Osaka
- Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
- Current Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
- Current Assignee Address: JP Osaka
- Agency: Wenderoth, Lind & Ponack, L.L.P.
- Priority: JPJP2018-063740 20180329
- International Application: PCT/JP2019/013531 WO 20190328
- International Announcement: WO2019/189555 WO 20191003
- Main IPC: C07D401/14
- IPC: C07D401/14 ; C07D403/14 ; A61P35/00 ; C07D213/84 ; C07D401/12 ; C07D403/12 ; C07D405/12 ; C07D405/14 ; C07D471/10 ; C07D487/10 ; C07D495/10
Abstract:
Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
Public/Granted literature
- US20210363130A1 HETEROCYCLIC COMPOUND Public/Granted day:2021-11-25
Information query
